Uncommon Cents Investing LLC Reduces Holdings in Integer Holdings Corporation $ITGR

Uncommon Cents Investing LLC reduced its holdings in shares of Integer Holdings Corporation (NYSE:ITGR) by 5.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,945 shares of the medical equipment provider’s stock after selling 160 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Integer were worth $362,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Integer in the first quarter worth approximately $33,337,000. Nuveen LLC acquired a new position in Integer during the first quarter valued at approximately $17,634,000. Millennium Management LLC raised its stake in shares of Integer by 2,408.8% during the first quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock valued at $14,531,000 after purchasing an additional 118,224 shares during the period. GAMMA Investing LLC raised its stake in shares of Integer by 8,697.6% during the first quarter. GAMMA Investing LLC now owns 78,123 shares of the medical equipment provider’s stock valued at $92,190,000 after purchasing an additional 77,235 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Integer by 40.2% during the first quarter. The Manufacturers Life Insurance Company now owns 213,741 shares of the medical equipment provider’s stock valued at $25,224,000 after purchasing an additional 61,273 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ITGR has been the subject of several recent research reports. Wells Fargo & Company lowered their price target on shares of Integer from $152.00 to $132.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. Truist Financial cut their price target on shares of Integer from $145.00 to $137.00 and set a “buy” rating for the company in a report on Friday, July 25th. Raymond James Financial cut their price target on shares of Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. Finally, Wall Street Zen raised shares of Integer from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $140.25.

Integer Trading Down 0.2%

Shares of ITGR stock opened at $101.59 on Monday. Integer Holdings Corporation has a 12 month low of $99.73 and a 12 month high of $146.36. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. The business’s 50 day moving average is $106.49 and its two-hundred day moving average is $114.57. The company has a market cap of $3.56 billion, a PE ratio of 44.75, a price-to-earnings-growth ratio of 0.80 and a beta of 1.03.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.02). The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the business earned $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. Equities analysts predict that Integer Holdings Corporation will post 6.01 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.